Navigation Links
Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
Date:10/19/2009

EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today it has submitted written notice to the NASDAQ Stock Market LLC ("NASDAQ") that NTI intends to file a Form 25 with the Securities and Exchange Commission ("SEC") on or about October 28, 2009 to effect the voluntary delisting of its common stock from NASDAQ, if NTI's stockholders approve the dissolution of the company pursuant to a Plan of Complete Liquidation and Dissolution at the special meeting of stockholders planned for Tuesday, October 27, 2009.

Details of NTI's plans to pay an extraordinary dividend, delist its common stock from the Nasdaq Capital Market, discontinue recording transfers of stock, cease its reporting obligations under the Securities Exchange Act of 1934, as amended, and distribute its net cash to stockholders can be found in a definitive proxy statement filed with the SEC on September 22, 2009.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

SOURCE Neurobiological Technologies, Inc.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
2. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center
3. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
4. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
5. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
6. Neurobiological Technologies Announces Suspension of Viprinex Development
7. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
8. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
9. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
10. Neurobiological Technologies Sets Date for First Quarter Financial Results
11. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... science is widely considered to be crucial for the ... to physician assistants and physical therapists, the future of ... of healthcare and science. Yet, for the second consecutive ... University of the Sciences ( http://www.usciences.edu ) ...
... NORTHAMPTON, England, June 15, 2011 , ... has announced it has hired Nicholas Tubb as its,new ... has joined Access,Legal from Challinors, clinical negligence ... Tubb has considerable experience in the sector ...
... 15, 2011 NeoStem, Inc. ("NeoStem" or the "Company") ... company with product and service revenues, global research and ... – U.S. adult stem cells, China adult stem cells, ... President of Strategic Business Development, will present at the ...
Cached Biology Technology:Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 2Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 3Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 4Access Legal Announces Appointment of Nicholas Tubb to Medical Negligence Team 2NeoStem to Present at Two Investor Events This Month 2NeoStem to Present at Two Investor Events This Month 3NeoStem to Present at Two Investor Events This Month 4
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... only in the world,s oldest oceans has shed new light ... Earth. , A scientific team led by Professor Robert Frei ... from Newcastle University, UK, and universities in Uruguay and Southern ... rise and fall of oxygen levels in the Earth,s atmosphere ...
... An animal study at Purdue University has shown that adding ... body absorb helpful compounds and also demonstrates the effectiveness of ... for these types of studies. Mario Ferruzzi, associate professor ... human intestinal cells to show that adding ascorbic acid to ...
... reporting a major improvement in their potential new treatment ... to Botox and cosmetic surgery. The non-invasive technique combines ... made of green tea extract. It works ten times ... alone, the researchers say. Their study is scheduled for ...
Cached Biology News:Ancient oceans offer new insight into the origins of animal life 2Model backs green tea and lemon claim, lessens need to test animals 2
... Essentials Kit provides all the necessary materials and ... mir Vana miRNA Bioarrays when using a ... mir Vana miRNA Labeling Kit. The kit ... BA10001) that should be spiked into your miRNA ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
... siRNA Tracker Intracellular Localization Kit provides a ... deliver siRNA, of your design, in an ... tracking experiments. Subcellular localization and functional inhibition ... following introduction of the labeled siRNA into ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
Biology Products: